Avinger posts loss on disappointing sales

August 14, 2018 By Nancy Crotti Leave a Comment

Avinger (NSDQ:AVGR) today posted a second-quarter losses-per-share that missed an analyst’s expectation, sending its share price down on Wall Street despite nearly halving its losses.

The Redwood City, Calif.-based medical device maker reported losses of -$6.6 million, or -98¢ per share, on sales of $2.1 million for the three months ended June 30, 2018. That compares with losses of -$12.8 million during Q2 2017 and amounts to a -14% top-line slide.

An analyst on The Street was looking for losses per share of -0.48¢ on sales of $2.6 million.

Positive news for the quarter included FDA clearance and initial sales of the company’s next-generation Pantheris image-guided atherectomy device and successful treatment of patients in several centers throughout the U.S. Avinger raised an additional $3.55 million in July 2018 from the sale of securities under a registered direct offering and hired new chief medical and financial officers.

“Receiving FDA clearance for our next generation Pantheris 3.0 was a key highlight of the second quarter and a significant milestone for Avinger. Following successful cases and positive physician feedback in initial U.S. sites, we are now focused on the commercial rollout of this next generation device to our installed base of accounts,” said Jeff Soinski, Avinger’s president & CEO, in a prepared statement. “We delivered strong sequential quarter revenue growth and made significant progress on the development of our pipeline products and in our clinical programs during the second quarter. We also added new capital to our balance sheet and made important new additions to our senior leadership team in recent months. I am pleased with the progress we are making as we return the company to growth and excited about our prospects for the future.”

Avinger’s share price fell by 6% to $1.20 at midday, nearly 10 times lower than one year ago.

Inside Hologic's evolving definition of women's healthcare

Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.

At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!

REGISTER NOW

Use code WOMENSHEALTH to save an additional 10%.

What you should know about today’s top trends in medtech
Medtech’s hottest topics in M&A, intellectual property, finance and regulation will be on the agenda at DeviceTalks Boston Oct. 8-11. Patent attorney David Dykeman from the Boston office of the global law firm Greenberg Traurig will moderate the Oct. 9 hot topics panel in which the discussion will center around: · M&A trends from the perspective of… […]
Olympus touts line of needles for GI disease improvement
Olympus is touting its new EZ Shot 3 Plus 25 G needles that is designed to help improve the staging of GI disease. The 25 G needle is an addition to the EZ Shot 3 Plus 19 G and 22 G needles that Olympus already markets. Olympus’s new EZ Shot 3 Plus 25 G needles… […]
Mindray North America picks Eastman medical polymers for patient monitors
Mindray is using Eastman’s medical polymers in its present generation of patient monitors in order to improve chemical resistance to cleaning/disinfection agents and increase device longevity, the companies recently announced. Thanks to the Eastman polymers, Mindray’s Passport series of bedside monitors, T1 monitor/module and Accutorr series of spot check monitors are now fully compatible with more than… […]
Cincinnati Children’s researchers report progress growing a human esophagus in a lab
It’s possible to use pluripotent stem cells to grow human esophageal organoids — another step toward the goal of someday bioengineering the entire esophagus and human gastrointestinal system in a lab, according to researchers at Cincinnati Children’s Center for Stem Cell and Organoid Medicine (CuSTOM). The Cincinnati Children’s researchers describe the advance as a first. Pluripotent stem… […]
How strong patent portfolios attract strategic investments and deals
Amassing strong patent portfolios helps medical device companies attract interest from strategic investors and potential acquirers. David J. Dykeman, Greenberg Traurig and Patrick West, Mirus Capital Advisors The medical device industry has demonstrated strong and sustainable growth in recent years. Given the aging population, increasing incidence of chronic and lifestyle diseases, emergence of artificial intelligence (AI)… […]
NucleusHealth wins investment from large Ohio health system
Cloud-based medical image exchange company NucleusHealth has landed an undisclosed “strategic investment” from Mercy Health, an Ohio–based health care system that is now a minority investor in the San Diego, Calif.-based company. NucleusHealth will use the money to help deliver Nucleus.io, the first cloud-based Picture Archiving Communications System (PACS) platform designed to use the security, scalability and… […]
Intuitive Surgical taps InTouch Health to develop platform-connected IoT
Telehealth developer InTouch Health said today it inked a multi-year licensing service agreement with Intuitive Surgical (NSDQ:ISRG) to deepen the robotic surgery giant’s Internet of Medical Things network connecting its da Vinci systems onto a single network. Santa Barbara-based InTouch Health said that its proprietary IoMT network is intended to allow healthcare companies to connect their surgical systems globally… […]
The 10 largest medical device companies in the world
Medtronic and Johnson & Johnson remain the world’s largest medical device companies. But after that, the roster is radically shifting amid a slew of mergers and acquisitions. In some cases such as GE, Philips and Siemens, major multinationals are breaking apart. We’ve sifted through data from public companies’ annual reports and other publicly disclosed information,… […]
SpineVision wins FDA nod, CE Mark for titanium TLIF cage
SpineVision recently announced that it has received FDA clearance and CE Mark approval for its titanium 3D laser-printed Hexanium TLIF cage for back surgery. Spine fusion surgery is used to stop the motion of a painful segment in the spine by fusing two of the vertebrae with a TLIF cage. The procedure is used to… […]
GI Dynamics raises $5 million for diabetes/obesity device
Investors have agreed to buy $5 million worth of GI Dynamics’ (ASX:GID) common stock, representing 6.9 million shares. The Lexington, Mass.-based company said it will use the money to fund the continued development of its EndoBarrier device and for general working capital. EndoBarrier is a plastic gut sleeve designed to treat type 2 diabetes and obesity… […]
Heidelberg Engineering wins FDA nod for upgraded eye imaging technology
The FDA has approved Heidelberg Engineering’s optical coherence tomography angiography module (OCTA), the company said today. The module is available for new and existing Spectralis upgradeable diagnostic imaging devices used to manage diabetic retinopathy, age-related macular degeneration and other macular diseases. OCTA is a noninvasive imaging technique that provides three-dimensional visualization of perfused ocular vasculature. Structural… […]